Work

An open-label clinical trial of RP2 and RP3 oncolytic immunotherapy in combination with atezolizumab and bevacizumab for the treatment of patients with advanced colorectal carcinoma.

Year: 2023

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2023.41.16_suppl.tps3628

Authors: Dale Randall Shepard, Muneeb Ahmed, Tanios S. Bekaii-Saab, Johannes Wolff

Institutions: Cleveland Clinic, Beth Israel Deaconess Medical Center, Mayo Clinic Hospital, Replimune Group, Inc. (United States)

Language: English

Topic: Virus-based gene therapy research

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4379282559

Cites:

Cited by: 1

Related to: 10